What is the 13F Pro Quality Score for TGTX?

13F Pro ranks TG THERAPEUTICS, INC. (TGTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TGTX's current score at https://13fpro.ai/company/TGTX (free sign-up required for the full ranking).

Which hedge funds own the most TGTX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TGTX include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/TGTX as soon as new 13F filings post.

Where does 13F Pro source TGTX data?

All TG THERAPEUTICS, INC. fundamentals and ownership data come directly from SEC EDGAR. TG THERAPEUTICS, INC. files with the SEC under CIK 1001316. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TGTX in?

TG THERAPEUTICS, INC. (TGTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives TGTX's revenue?

Per TG THERAPEUTICS, INC.'s latest 10-Q filed with the SEC on 2026-08-05, the biggest revenue drivers are: Product revenue, net ($235.8M); U.S. BRIUMVI net product sales ($227.7M); Sales to Neuraxpharm (ex-U.S. partner) ($8.1M). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/TGTX.

What are TGTX's largest expenses?

TG THERAPEUTICS, INC.'s latest 10-Q reports these as the largest expense items: Other research and development ($87.3M); Other selling, general and administrative ($62.3M); Cost of revenue ($41.2M). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is TGTX research updated on 13F Pro?

TGTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

TG THERAPEUTICS, INC.(TGTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1001316 TGTX stock profile & AI dashboard →

13F Pro Quality Score

69.3/100

Rank #276 of 2,961 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

94.8/100

Profitability

98.4/100

Balance Sheet

98.9/100

Earnings Quality

48.0/100

Free Cash Flow

32.9/100

Institutional Flow

67.5/100

Revenue Scale

45.9/100

Dilution Risk

15.7/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why TGTX Scores 69/100

exact factor attribution · 2026-09-11

TGTX's composite is driven by revenue growth and profitability, held back by free cash flow and shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.0 pts

95th pct

Profitability

+7.3 pts

98th pct

Capital efficiency

+4.9 pts

99th pct

Earnings growth

+2.4 pts

98th pct

Institutional flow

+0.9 pts

68th pct

Earnings quality

-0.2 pts

48th pct

Scale

-0.6 pts

46th pct

Shareholder dilution

-1.7 pts

16th pct

Free cash flow

-2.6 pts

33th pct

Latest change (2026-08-05): 68 → 62 · ↓ Capital efficiency 99→69; ↓ Profit margin 96→77; despite ↑ Free cash flow 19→35

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

TGTX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for TG THERAPEUTICS, INC. (TGTX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TGTX at 69.3/100 on a 32-signal composite quality model, placing it at rank #276 of 2,961 stocks — the top 10% of the AI-ranked universe. TGTX scores in the top quartile across balance sheet strength (98.9), profitability (98.4), revenue growth (94.8). Areas of concern include free cash flow (32.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 15.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), TG THERAPEUTICS, INC. reports quarterly revenue of $240.3M, net income of $7.8M, free cash flow of $39.0M. Top institutional holders of TGTX by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, STATE STREET, based on the most recent SEC filings. TGTX trades on the Nasdaq exchange and files with the SEC under CIK 1001316. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TGTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TG THERAPEUTICS, INC. directly from SEC EDGAR. TG THERAPEUTICS, INC.'s 13F Pro composite quality score has ranged between 12 and 77 since 2021, currently 69.3 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about TG THERAPEUTICS, INC.

Quirks, history, and lore behind TGTX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · focused on treatments for B-cell diseases and blood cancers.
2
The Numbers
A small-cap biotech with minimal product revenue for most of its life — the classic story of a company that burns cash while waiting for its FDA approvals to print money.
3
The History
Founded in the early 2000s, the company spent years developing a pipeline targeting hematologic malignancies and autoimmune disorders before landing its first commercial product.
4
The Secret
Its approved drug Ukoniq hit the market but was later voluntarily withdrawn — a brutal reminder that the FDA giveth and the safety data taketh away.
5
The Lore
The company regrouped and scored a major win with ublituximab, an anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis — a pivot that surprised many skeptics.
6
The Giveaway
Its MS therapy Briumvi launched to commercial fanfare, and its ticker — two letters that are basically just its own initials doubled — is one of the most on-the-nose symbols on Wall Street.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving TGTX's Business? Latest 10-Q Breakdown

✓ 32/32 datapoints verified

AI-extracted from TG THERAPEUTICS, INC.'s 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 revenue grew to $240.3M from $141.1M on BRIUMVI uptake, but net income fell to $7.8M from $28.2M as R&D and interest expense surged.

Biggest Revenue Drivers

Product revenue, net$235.8M

Greater market penetration of BRIUMVI in the United States and commercial product sales supplied to Neuraxpharm

License, milestone, royalty and other revenue$4.5M

$3.6 million of Neuraxpharm royalty revenue plus $0.9 million for development and regulatory activities

Biggest Revenue Drivers

Total revenue: $240.3M

Product revenue, net$235.8M

Greater market penetration of BRIUMVI in the United States and commercial product sales supplied to Neuraxpharm

Within Product revenue, net

U.S. BRIUMVI net product sales$227.7M

Net product sales of BRIUMVI in the United States, versus $138.8 million a year ago

Sales to Neuraxpharm (ex-U.S. partner)$8.1M

Optional purchases of BRIUMVI supplied under the Commercialization Agreement; there were no such sales in the prior-year quarter

License, milestone, royalty and other revenue$4.5M

$3.6 million of Neuraxpharm royalty revenue plus $0.9 million for development and regulatory activities

Largest Expense Items

Other research and development$87.3M

Increase from $27.5 million driven primarily by manufacturing expense for subcutaneous development work and other R&D manufacturing activities

Other selling, general and administrative$62.3M

Increase from $43.5 million due to marketing and media spend and personnel-related costs supporting BRIUMVI commercialization

Cost of revenue$41.2M

Increase from $18.9 million driven by growth in BRIUMVI U.S. sales volume and sales to Neuraxpharm; includes $24.4 million LFB royalty

Interest expense$16.6M

Increase from $6.7 million mainly due to the First Amendment to the Financing Agreement with Blue Owl Capital

Margins: Gross margin on BRIUMVI U.S. net product revenue remained approximately 87% in the quarter; total gross margin was approximately 83%, reflecting Neuraxpharm sales and other revenue that carry different margins.

Watch Items from the Filing

Four specialty distributors accounted for 40%, 29%, 19% and 12% of gross product revenue in the quarter, and 36%, 23%, 28% and 12% of product accounts receivable.
March 2026 refinancing replaced the $250 million term loan with a $750 million Blue Owl facility maturing 2031; loan payable non-current is $745.4 million and secured by substantially all assets.
Net income fell to $7.8 million from $28.2 million despite revenue growth; the quarterly effective tax rate rose to 24.0% from 8.8% after the valuation allowance release.
Non-cancelable purchase commitments total $219.8 million, with $105.7 million and $114.1 million expected in 2027 and 2028; the sole bulk drug substance supplier is located outside the U.S., exposing inventory to tariffs.
Phase 3 ENHANCE met its primary endpoint for a single 600 mg initiation infusion, and subcutaneous ublituximab Phase 3 topline is expected around year-end 2026 or Q1 2027.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$240.3M

Net Income

Q2 2026

$7.8M

Free Cash Flow

Q2 2026

$39.0M

ROIC

Q2 2026

6.4%

D/E Ratio

Q2 2026

1.23

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+87.3% YoY

$616.3MFY 2025

FY22 $2.8MFY23 $233.7MFY24 $329.0MFY25 $616.3M

Net Income

+1812.4% YoY

$447.2MFY 2025

FY22 $-223.8MFY23 $12.7MFY24 $23.4MFY25 $447.2M

Operating Income

+194.1% YoY

$123.3MFY 2025

FY22 $-218.3MFY23 $20.6MFY24 $41.9MFY25 $123.3M

EPS (Diluted)

+1746.7% YoY

$2.77FY 2025

FY22 $-1.65FY23 $0.09FY24 $0.15FY25 $2.77

Total Assets

+84.1% YoY

$1.06BFY 2025

FY22 $193.6MFY23 $329.6MFY24 $577.7MFY25 $1.06B

Total Debt

+0.5% YoY

$245.6MFY 2025

FY22 $71.1MFY23 $100.4MFY24 $244.4MFY25 $245.6M

Op. Cash Flow

+38.9% YoY

$-24.8MFY 2025

FY22 $-176.2MFY23 $-31.4MFY24 $-40.5MFY25 $-24.8M

Free Cash Flow

+38.4% YoY

$-25.0MFY 2025

FY22 $-176.2MFY23 $-31.4MFY24 $-40.6MFY25 $-25.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$616.3M +87.3%	$329.0M +40.8%	$233.7M +8290.0%	$2.8M -58.4%	$6.7M +4300.7%	$152.0K
Net Income	$447.2M +1812.4%	$23.4M +84.5%	$12.7M +105.7%	$-223.8M +35.7%	$-348.1M	—
Operating Income	$123.3M +194.1%	$41.9M +103.2%	$20.6M +109.5%	$-218.3M +36.7%	$-344.8M -26.0%	$-273.6M
EPS (Diluted)	$2.77 +1746.7%	$0.15 +66.7%	$0.09 +105.5%	$-1.65 +37.3%	$-2.63 -8.7%	$-2.42
Total Assets	$1.06B +84.1%	$577.7M +75.3%	$329.6M +70.3%	$193.6M -49.0%	$379.6M -39.3%	$625.6M
Total Debt	$245.6M +0.5%	$244.4M +143.4%	$100.4M +41.1%	$71.1M +3.5%	$68.7M +32.0%	$52.1M
Operating Cash Flow	$-24.8M +38.9%	$-40.5M -29.0%	$-31.4M +82.2%	$-176.2M +40.4%	$-295.6M -37.8%	$-214.5M
Free Cash Flow	$-25.0M +38.4%	$-40.6M -29.1%	$-31.4M +82.2%	$-176.2M +40.5%	$-296.0M -37.8%	$-214.9M

Get alerted when TGTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TG THERAPEUTICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TGTX

BlackRock, Inc.
$1.2B22,050,045 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$437.5M7,963,266 sh
STATE STREET CORP
$427.8M7,786,471 sh
VANGUARD CAPITAL MANAGEMENT LLC
$337.8M6,149,403 sh
GEODE CAPITAL MANAGEMENT, LLC
$200.1M3,642,216 sh
D. E. Shaw & Co., Inc.
$186.8M3,400,808 sh
Soleus Capital Management, L.P.
$160.9M2,927,895 sh
PRICE T ROWE ASSOCIATES INC /MD/
$152.1M2,767,656 sh
Clearbridge Investments, LLC
$145.6M2,650,192 sh
CONGRESS ASSET MANAGEMENT CO /MA
$142.9M2,600,123 sh

Fund	Value	Shares
BlackRock, Inc.	$1.2B	22,050,045
VANGUARD PORTFOLIO MANAGEMENT LLC	$437.5M	7,963,266
STATE STREET CORP	$427.8M	7,786,471
VANGUARD CAPITAL MANAGEMENT LLC	$337.8M	6,149,403
GEODE CAPITAL MANAGEMENT, LLC	$200.1M	3,642,216
D. E. Shaw & Co., Inc.	$186.8M	3,400,808
Soleus Capital Management, L.P.	$160.9M	2,927,895
PRICE T ROWE ASSOCIATES INC /MD/	$152.1M	2,767,656
Clearbridge Investments, LLC	$145.6M	2,650,192
CONGRESS ASSET MANAGEMENT CO /MA	$142.9M	2,600,123

Companies Similar to TGTX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

KRYS

Krystal Biotech, Inc.

AI score

Similar quality profile · 25 shared holders

Soleus Capital Management, L.P.Hood River Capital Management LLC Bridgewater Associates, LP

ACAD

ACADIA PHARMACEUTICALS INC

AI score

Similar quality profile · 16 shared holders

Edgestream Partners, L.P.Point72 Europe (London) LLP FRED ALGER MANAGEMENT, LLC

NBIX

NEUROCRINE BIOSCIENCES INC

AI score

Similar quality profile · 11 shared holders

Hood River Capital Management LLC Clearbridge Investments, LLC Bridgewater Associates, LP

KNSA

Kiniksa Pharmaceuticals International, plc

AI score

Similar quality profile · 11 shared holders

Penn Capital Management Company, LLC Soleus Capital Management, L.P.CASTLEARK MANAGEMENT LLC

LGND

LIGAND PHARMACEUTICALS INC

AI score

Similar quality profile · 16 shared holders

CONGRESS ASSET MANAGEMENT CO /MA Penn Capital Management Company, LLC CASTLEARK MANAGEMENT LLC

CPRX

CATALYST PHARMACEUTICALS, INC.

AI score

Similar quality profile · 12 shared holders

Bridge City Capital, LLC Legato Capital Management LLC FIRST CITIZENS BANK & TRUST CO

INCY

INCYTE CORP

AI score

Similar quality profile · 7 shared holders

Bridgewater Associates, LP 1832 Asset Management L.P.Edgestream Partners, L.P.

INDV

Indivior Pharmaceuticals, Inc.

AI score

Similar quality profile · 11 shared holders

Soleus Capital Management, L.P.Bridgewater Associates, LP DIADEMA PARTNERS LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TGTX on your watchlist

Track score changes the day TG THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TGTX a good stock to buy?

13F Pro's AI-powered analysis of TG THERAPEUTICS, INC. (TGTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TGTX are available on the TGTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TGTX is classified as a mid company.

Which hedge funds own TGTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TGTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TG THERAPEUTICS, INC.'s investment landscape.